Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid.
This study evaluates the modulation of striatum vulnerability to quinolinic acid (QA) by the nitrostriatal projection. Unilateral lesioning of the substantia nigra with 6-hydroxydopamine markedly reduced the volume of striatal necrosis observed 3 days after local injection of quinolinic acid (150 nmol). This result is consistent with the concept that the nigrostriatal pathway potentiates the vulnerability of striatum to excitotoxic damage.
Buisson
A
A
Laboratoire de Pharmacologie, Faculté des Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.
Pateau
V
V
Plotkine
M
M
Boulu
R G
RG
D000818:Animals; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects*; D003891:Desipramine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D008297:Male; D009410:Nerve Degeneration / Q000187:drug effects; D009434:Neural Pathways / Q000187:drug effects; D016627:Oxidopamine / Q000494:pharmacology; D017378:Quinolinic Acid; D011805:Quinolinic Acids / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects*
D011805:Quinolinic Acids; D016627:Oxidopamine; D017378:Quinolinic Acid; D003891:Desipramine; D004298:Dopamine